%0 Journal Article
%T NF-kappaB activation is associated with homocysteine-induced injury in Neuro2a cells
%A Nadia Ferlazzo
%A Salvatore Condello
%A Monica Curr辰
%A Giulia Parisi
%A Riccardo Ientile
%A Daniela Caccamo
%J BMC Neuroscience
%D 2008
%I BioMed Central
%R 10.1186/1471-2202-9-62
%X A 4 h exposure to homocysteine in a concentration range of 10每100 米M did not affect cell viability and ROS production in Neuro2a cell cultures. Instead, ROS levels were increased by two-three folds in cells treated with 250 米M and 500 米M homocysteine, respectively, in comparison with control cells. Also, the highest homocysteine dose significantly reduced the viable cell number by 40%. Notably, the treatment with homocysteine (250 米M每500 米M) in the presence of antioxidants, such as N-acetylcysteine and IRFI 016, a synthetic 汐-tocopherol analogue, recovered cell viability and significantly reduced homocysteine-evoked increases in ROS production. Moreover, antioxidants, particularly IRFI 016, were able to counteract NF-百B activation induced by 250 米M homocysteine.Cell treatment with 250 米M homocysteine also triggered the onset of apoptosis, as demonstrated by the increased expression of early apoptotic markers such as Bax, caspase-3 and p53. In contrast, Bcl2 expression was not affected by homocysteine exposure. Interestingly, the specific inhibition of NF-百B nuclear translocation by the synthetic peptide SN50 was able to almost completely suppress the homocysteine-evoked rises in pro-apoptotic protein expression as well as in caspase-3 activity. Further, also IRFI 016 and N-acetylcysteine were able to significantly reduce caspase-3 activation induced by homocysteine treatment.These observations suggest an involvement of redox state alterations and activated NF-百B in apoptosis onset triggered by homocysteine in neuroblastoma cells Neuro2a. However, further investigations are needed to characterize molecular events involved in the NF-百B activation induced by homocysteine.Homocysteine (Hcy) is a non-proteic sulfur-containing amino acid product of methionine metabolism. Hyperhomocysteinemia is determined by genetic factors, such as deficiency in enzyme activities involved in homocysteine remethylation and transulphuration pathways, and/or reduced dietary intake of folate
%U http://www.biomedcentral.com/1471-2202/9/62